Condition
Platelet Transfusion Refractoriness (PTR)
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Not Yet Recruiting1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07635511Phase 3Not Yet Recruiting
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies
NCT03712618Phase 2TerminatedPrimary
The SOLID Platelet Study
Showing all 2 trials